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Abstract
Background: Beta thalassemia major is a severe inherited form of hemolytic anemia that results from ineffective
erythropoiesis. Allogenic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative
therapy. Unfortunately, the subgroup of adult thalassemia patients with hepatomegaly, portal fibrosis and a history
of irregular iron chelation have an elevated risk for transplantation-related mortality that is currently estimated to
be about 29 percent.
Discussion: Thalassemia patients may be faced with a difficult choice: they can either continue conventional
transfusion and iron chelation therapy or accept the high mortality risk of HSCT in the hope of obtaining complete
recovery.
Throughout the decision making process, every effort should be made to sustain and enhance autonomous
choice. The concept of conscious consent becomes particularly important. The patient must be made fully aware
of the favourable and adverse outcomes of HSCT. Although it is the physician’s duty to illustrate the possibility of
completely restoring health, considerable emphasis should be put on the adverse effects of the procedure. The
physician also needs to decide whether the patient is eligible for HSCT according to the “rule of descending
order”. The patient must be given full details on self-care and fundamental lifestyle changes and be fully aware
that he/she will be partly responsible for the outcome.
Summary: Only if all the aforesaid conditions are satisfied can it be considered reasonable to propose unrelated
HSCT as a potential cure for high risk thalassemia patients.
Background
Beta thalassemia major is a severe hereditary hemolytic
anemia that arises from reduced or absent synthesis of
the hemoglobin subunit beta. Clinical presentation
occurs between the ages of 6 months and 2 years. Red
cells are rapidly destroyed, freeing large amounts of iron
that are deposited in organs and tissues. Hyperabsorp-
tion of iron by the gastrointestinal tract, driven by the
ineffective erythropoiesis, contributes to hemochromato-
sis-induced organ damage. Iron overload is furthermore
aggravated by the frequent transfusions required to
maintain blood-oxygen carrying capacity in these
patients. Sequelae include severe anemia, hepatic fibrosis
and cirrhosis, diabetes mellitus, hypogonadism, growth
retardation, sexual immaturity, moderate to severe
pulmonary syndromes and cardiac disorders. Myocardial
disease is by far the most important life-limiting compli-
cation and is responsible for about 70 percent of deaths
in these patients [1].
The survival of patients with thalassemia major is con-
tinuously improving, but despite the advances made in
iron chelation therapy [2,3], the prevalence of severe
complications such as heart failure, arrhythmias, and
diabetes remains high. Allogenic HSCT remains the
only potentially curative treatment for patients with tha-
lassemia [4]. The outcome of HSCT partially depends
upon the patient’s pre-transplantation clinical condi-
tions, particularly the extent of hepatomegaly and/or
liver fibrosis and the magnitude of iron accumulation.
An HLA identical sibling is the donor of choice for
patients requiring allogenicH S C T .A f t e rs u c c e s s f u l
HSCT, patients receive regular phlebotomy therapy until
iron stores return to normal [5]. When an HLA-
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unrelated voluntary donor is a feasible alternative pro-
vided that the donor is selected according to stringent
HLA compatibility criteria. Experience has shown that
by applying highly stringent criteria for donor selection,
the outcome of HSCT is comparable to that obtained
when the donor is a compatible sibling [6]. Unfortu-
nately, adult thalassemia patients belonging to risk class
3 of the Pesaro classification (patients with hepatome-
galy, portal fibrosis and a history of irregular iron chela-
tion) have an elevated risk for transplantation-related
mortality (TRM) which is currently estimated to be
about 29 percent [7]. The experience acquired in our
bone marrow transplantation center confirms this per-
centage. So far, 36 high risk thalassemia patients (16
males and 20 females) aged 16 years or older (median
22 yrs, range 16 - 37 yrs) have received HSCT in our
Center. Five-year overall survival (median follow-up per-
iod of 5.8 years) was 75% while the cumulative incidence
of TRM was 25%. Nine patients died of transplantation-
related causes. Furthermore, 21.5% of the survivors
developed chronic graft-versus-host disease (GvHD).
Discussion
A decisive choice
All things considered, the clinical hematologist is
faced with a multitude of risk factors (disease severity,
early onset, the difficult management and treatment of
complications of beta- thalassemia major) as well as the
demanding task of identifying patients likely to incur a
bad outcome [8]. Unfortunately, it is difficult, if not
impossible, to foresee the outcome for each patient.
Indeed, our ability to predict the burdens and benefits
of HSCT is very poor. A well known method is to stra-
tify patients from risk class 1 (5% of mortality) to risk
class 3 (29% of mortality) of the Pesaro classification.
After that, all the elements we possess to communicate
risk to the patient are statistic. Unfortunately, a 29%
mortality risk could be perceived by the patient as a
severe threat. Therefore, the doctor’s ability to commu-
nicate the risks and benefits and the patient’s capacity
to understand both the elements of risk and the signifi-
cance of the transplantation procedure are crucial to the
ultimate decision of what the patient must do.
Hence, the patient is faced with a decisive choice: he/
she can either undergo HSCT with a good probability of
cure but a high chance of death or continue to rely on
conventional transfusion and chelation therapy. From
this it follows that the choice of HSCT needs to be sus-
tained by in-depth knowledge of the quality of life of
both transplanted and untransplanted patients. The
WHO defines quality of life (QoL) as: « an individual’s
perception of their position in life in the context of the
culture and value systems in which they live and in
relation to their goals, expectations, standards and con-
cerns. It is a broad ranging concept affected in a com-
p l e xw a yb yt h ep e r s o n ’s physical health, psychological
state, personal beliefs, social relationships and their rela-
tionship to salient features of their environment» [9].
Some of the major clinical and psychological aspects of
thalassemia are: the effect of chronic illness on family
stability and dynamic family structure, bone deformities
and short stature leading to poor self image, frequent
hospital appointments for transfusions, overnight subcu-
taneous infusions, poor sexual development, impaired
fertility, disease or therapy-related complications and
uncertainties about the future [10]. Additional psycholo-
gical and social problems may arise from interference of
the aforesaid aspects with employment and education.
Overall, despite the progress made, prolonged depen-
dency on family care continues to jeopardize these
patients’ right to self determination and autonomy.
None the less, patients who are compliant with con-
ventional treatment modalities can expect to enjoy a
good quality of life with a life expectancy of about 50
years. The life expectancy in the era of new chelators,
other therapies and non-invasive diagnostics is not yet
known. A recent paper published by Caterina Borgna-
Pignatti [11] provides valuable data on the quality of life
of patients with thalassemia major and the survival rates
of the different birth cohorts.
On the other hand, HSCT offers a definitive cure but
is burdened by significant morbidity and mortality. Even
if HSCT is successful, the risk of serious complications
such as acute and chronic GvHD remains. Chronic
GvHD can have a negative impact on an individual’s
general health and mental health, and can lead to the
development of functional impairment and activity lim-
itations. We also underscore that the QoL and overall
health of individuals who have been successfully treated
for chronic GvHD are not different from those with no
history of chronic GvHD. Additionally, endocrinopa-
thies, particularly gonadal dysfunction, can still occur.
Therefore, it becomes crucial to consider the dilemmas
that arise from the choice of HSCT in order to empha-
size under what conditions this therapeutic approach
may be considered the best choice for the patient.
Ethical issues concerning the principles of beneficence,
non maleficence and autonomy
Regular blood transfusions and iron chelation therapy
have transformed thalassemia from a rapidly fatal dis-
ease to a chronic disorder compatible with prolonged
survival. The recent availability of oral iron chelators
and the progress made over the past 30 years toward
understanding the genetic defects and pathogenic
mechanism underlying thalassemia syndromes, has led
to the development of innovative therapeutic procedures
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the quality of life of affected patients [12,13]. However,
despite the advances made, complications such as inade-
quate transfusions, transfusion transmitted viral diseases,
allo-sensitization, liver and cardiac disturbances and iron
chelation toxicity, keep arising. Moreover, additional
previously undescribed complications (thromboembolic
episodes and atherogenesis-related pathologies) are now
being recognized. Alternatively, the elective option of
HSCT can greatly enhance quality of life, if not only by
removing the inconvenience caused by iron chelation
and transfusion therapy. Within this context, several
ethical dilemmas become apparent:
a - Is it reasonable to consider HSCT a feasible
option, capable of achieving the good of the patient in a
situation where the probability of harm is very high?
b - How can we put the patient in a condition to
choose freely? In other words: how can physicians fully
respect and support the patient’s autonomous choice.
c - Is every patient a good candidate for HSCT or is it
mandatory to screen for suitable patients and, if so,
which criteria should be used?
The good of the patient
It is the undeniable duty of the physician to do what is
best for the patient. The concept of good care is firmly
rooted and represents a widespread aim in medical
science. Although unrelated HSCT makes it possible to
achieve this goal, the risk of maleficence is high. There-
fore, even after the informed consent process has been
completed and the therapeutic procedure has started,
patient-physician communication must continue in
order to reach the best outcome. The ethical concept
founding the physician’s task may be well expressed by
the golden rule: t r e a to t h e r so n l yi nw a y st h a ty o u ’re
willing to be treated in the same exact situation [14]. As
Sydenam said, we offer to the sick man the same thera-
peutic options as we would claim for ourselves. Our
experience in the clinical setting suggests that a fair
decision cannot exclusively be based on the physician’s
clinical judgement. In taking the decision, the physician
must come to terms with the needs of the patient. The
p a t i e n ti sau n i q u ea n dv a l u a b l ep e r s o na n dn o tj u s ta
disease to be treated. Albeit scientific knowledge of the
disease is essential, it is only an element of clinical jud-
gement. A high standard of patient care can only be
achieved if the physician applies a more holistic
approach. In fact, the healing relationshipi sn o ts i m p l y
a contract based on scientific authority, but presupposes
the virtue of the physician to acknowledge the “attri-
butes of the patient as a person” [15]. The issue is not
simply “to cure” but “to take care” of the patient [16].
Alongside the clinical findings, it is of fundamental
importance to build a physician-patient relationship
based on the virtues of prudence, sharing, attention,
willingness and so on. Above all, it is mandatory to indi-
viduate the main moral problem requiring attention. As
mentioned previously, there is a high probability of mal-
eficence for patients undergoing HSCT: initially, the
large majority suffer relevant worsening of their already
endangered health and about 25 percent die within one
year [17]. This does not make it easy to apply the Hip-
pocratic rule “Primum non nocere”,s i n c et h e r ei sa n
elevated risk (one every four patients) of severely harm-
ing - till his/her death - the patient. If we consider the
central position of beneficence in medical ethics, HSCT
would appear, at least prima facie, as being too hazar-
dous to be suggested as a valid alternative to conven-
tional treatment in high risk thalassemia patients.
However, this is counterbalanced by the ability of HSCT
to completely restore health, so much so that many
patients consider themselves as “reborn“ after HSCT and
use the date of engraftment to celebrate their birthday
[18]. In a pharmacological experimentation it would be
unacceptable to tolerate such a high risk of unpleasant
side effects in order to reach a beneficial outcome. And
here we are not dealing with an advantageous result
that may be burdened by the presence of some unplea-
sant side effects but we are faced with the probability of
a potentially detrimental and irreversible consequence of
treatment combined with absence of the desired out-
come. Consequently, it can be said that unrelated HSCT
for thalassemia is more similar to an “all-or-nothing“
situation. In a life-threatening situation such as severe
acute leukemia or lymphoma, where HSCT is used as a
last resort to avoid death, it is beyond dispute that
patients who have a suitable donor should be given the
opportunity to undergo HSCT. However, the situation is
quite different when the alternative is an expected life-
span of twenty years or more.
In the light of these considerations the problem is not
only who is the best candidate to undergo to HSCT but,
more radically, if the proposed procedure is consistent
with the fundamental aim of medicine, that is benefi-
cence. Any negative answer to this question would let
the subject drop. For example, the eminent philosopher
William Frankena treats the principle of beneficence as
being divisible in four parts: a - One ought not inflict
evil or harm; b - One ought to prevent evil or harm; c -
One ought to remove evil or harm; d - One ought to do
or promote the good [19]. These four sub principles are
serially arranged so that in circumstances of conflict the
first overrides the second, the second takes precedence
over the third and so on. Being Frankena right, it would
be hard to consider HSCT a good choice. Other Philo-
sophers clearly distinguish between beneficence and
non-maleficence. Obligations not to harm others are
distinct from those to help others. Sometimes, the
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the one to promote the good, but in a changing context,
the obligation to try to promote the good outweighs the
concept of non-maleficence [20]. Given the fact that in
many situations benefits cannot be achieved without
inflicting harm, many writers in the field of medical
ethics retain that one must accept substantial risk in
order to safeguard life or restore health. If we consider
the delicate balance between the harms and benefits of
unrelated HSCT for thalassemia, it clearly emerges that
the decision for HSCT must account for the fact that
thalassemia patients have a valid alternative and that is,
to continue their life with conventional therapeutic sup-
port. Yet, in the light of our previous observations, we
retain that it is reasonable and appropriate for the physi-
cian to propose HSCT provided that the patient has a
central role in the decision-making process in concor-
dance with the moral principle of respect for autonomy.
The autonomy of the patient
Decision-making in medicine requires the respect of
individual freedom, dignity and moral values. In the
past, the physician was the one to take the final deci-
sion, regardless of the relationship with the patient [21].
Physicians had a paternalistic approach, recommending
what they felt was best for the patient. The growth of
liberalism with its many social changes has been a chal-
lenge to paternalism over the last few decades. The new
paradigm is founded on the respect for autonomy and
high ranking of principles and today represents one of
the most important guides to reasoning in bioethics.
Autonomous action is analyzed in terms of normal
choosers who act: 1 - intentionally; 2 - with understand-
ing; 3 - without controlling influences that determine
their action.
Physicians are more and more aware that they cannot
heal a person solely by curing the disease. Beneficence
cannot be achieved without full respect for patient
autonomy. The patient should always be given the last
word and be entitled to freely accept or decline the pro-
posed therapeutic measures and/or treatment options.
No-one should be coerced into unwanted behaviours.
We completely agree with the statement made by
George Surbled in 1895: «the patient has the right to
refuse any kind of trial or therapy simply barricading
himself/herself behind his/her wish, without presenting
any justification» [22]. Hence, the responsibility of the
physician is to provide all the elements that will assist
the patient in the decision-making process. A well-pon-
dered choice and conscious consent go hand in hand.
Consent is essential to patient autonomy, not only
intended as a capacity for independent decision and
action but, above all, conscious decision and action [23].
The pursuit of conscious consent is paramount and the
physician needs to be reminded that respecting the free-
dom of the patient is part of the goal of his profession
and that awareness is the only ground where freedom
can be respected.
Consciousness encompasses free will and indepen-
dence of choice. We agree with Paul Ramsey when he
portrays consent as “the cardinal canon of loyalty join-
ing men together in medical practice and investigation”
[24]. In the document Information and Consent for
Anesthesia, issued by the Association of Anesthetists of
Great Britain and Ireland, the term “informed consent”
is replaced with “express consent” [25]. Although the
authors clearly distinguish between the duty to obtain
informed consent and the obligation to warn patients of
the risks of a procedure, a considerable amount of ambi-
guity remains. The consent may be informed, clear, pre-
cise and explicit, and yet fail to fulfill the most crucial
task: patient awareness. Shared decision-making is of
fundamental importance when considering the option of
HSCT. The physician’sr o l ei st op r o v i d eac l e a rp i c t u r e
of the patient’s current clinical situation and to carefully
explain what the situation is likely to be in the future.
The physician should aim at developing a high level of
mutual understanding with the patient. Only if the
patient is made fully aware of the possible risks and
benefits of a proposed treatment is it possible to respect
autonomy and consciousness. In the case of HSCT the
patient’s autonomy may be undermined in several ways.
Bias in the perception of risks can lead the patient to
misunderstand the advantages and disadvantages of
HSCT. The understandable desire for recovery may
induce the patient to perceive only the positive aspects
and to neglect the real risk of danger of the procedure;
at the same time the possibility of a definitive cure
could lead the physician to emphasize the favourable
outcomes of the procedure and to minimize the adverse
effects. In both cases, the patient is unable to make a
free and conscious choice. Furthermore, many people
possess an unrealistic optimism that may lead them to
believe that the specific risks are significantly less than
objective probability might suggest [26]. There is plenty
of evidence demonstrating that the information supplied
during the decision-making process is often not well
understood and, consequently, that the decision to
undergo HSCT cannot be considered to be truly auton-
omous. Some studies suggest that people are more
prone to understand qualitative rather than quantitative
items [27]. Therefore, it should not be assumed that the
supply of a large amount of information is the best way
to ensure patient awarenes s .T h ed i f f e r e n c eb e t w e e n
communicated and perceived data can be striking. This
is not necessarily caused by poor communication but is
rather due to the misunderstanding that the volume of
information corresponds to its comprehension. Often
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tion, the patient loses the central point; other times the
amount of information may be appropriate but the phy-
sician is not sufficiently involved. Information can be
useful in achieving awareness but it does not correlate
with understanding. When the negative consequences of
a proposed treatment strategy are discussed with the
patient there is generally a rise in the discrepancy
between the information conveyed by the physician and
the information perceived by the patient [28]. This
makes it important to emphasize the adverse and dra-
matic effects of HSCT, particularly the development of
severe acute and/or chronic GvHD and the possibility of
death. Communication skills also have their importance.
A therapy reported to be 60 percent effective would be
evaluated more favourably than a 40 percent failure rate,
even though the two statements are objectively equal
[29]. Preferably, the physician should use the negative
statement to ensure that the patient fully grasps the
meaning. This approach is more challenging but it is
not by denying the risks that we act on the patient’s
behalf. The burden of chronic illness coupled to a des-
perate hope for recovery often leads the patient to
underestimate the significance of adverse effects. The
Medical Defense Union of London clearly asserts: “Doc-
tors...have a duty to explain to the patient, in non-tech-
nical language, the nature, purpose and material risks of
the proposed procedure” [30].
The following steps are essential to conscious consent:
1 - patients must be made aware of their overall medical
condition; 2 - physicians must communicate the reasons
for which the treatment is recommended; 3 - the bene-
fits of HSCT must be clearly explained, but at the same
time, therapy-related risks need to be vigorously
stressed. The physician must scrupulously check that
the patient has clearly and distinctly understood; 4 -
finally, the physician needs to discuss the clinical fea-
tures and prognosis of the patient in relation to conven-
tional treatment schemes.
The process of understanding can be slow and labor-
ious and makes it important for the physician to exert
the virtues of prudence, patience, attentiveness and
understanding to the best of his ability. Patients must be
given sufficient time to take-in and ponder their choices.
All these efforts combined should guarantee an accepta-
ble level of awareness with full respect for patient
autonomy. However, conscious consent only partially
solves the problem. Another important ethical aspect is:
Who is the best candidate for HSCT and who is respon-
sible for enrollment? The second question is easy to
answer since the physician is the only one to possess
the necessary authority, knowledge and competence to
decide who must or must not undergo HSCT. What
calls for additional ethical reflection is the choice of the
best candidate for HSCT. Whether a patient is suitable
or not remains a difficult decision based on complex cri-
teria, including objective and subjective data.
The right patient
We believe that in order to choose the right patient it is
not sufficient to consider only the clinical aspects. Such
criteria would include too many patients and the infor-
mation collected would be too general. We need to take
into account other patient characteristics along with
some environmental factors.
First of all, the physician must make sure that the
patient possesses sufficient physical and psychological
coping abilities to deal with all the complex aspects of
unrelated HSCT.
The patient must be capable of understanding what the
doctor is doing, why he/she is doing it, what the alterna-
tives may be, and what the future will mean for the things
he/she values most. The capability of understanding
comprises at least three factors: natural sensibility, educa-
tional completeness and attentiveness. All these factors
contribute to the assessment of the patient’s competence.
The concept of competence embraces the ability to
understand information concerning important decisions
related to one’s health, to appreciate the significance of
such decisions in relationship to one’s own life as well as
the ability to use the information to reason, choose and
express one’s choice [31].
The general rule could be expressed in this way: as
much as the person is lacking in knowledge, motivation
and capability of free decision, just as much should we
be reluctant to enroll these patients for unrelated HSCT.
Furthermore, the physician needs to assess whether
the patient has the capability to make the necessary life-
style changes (for example, increased self care for ade-
quate symptom management during the post-
transplantation course). Thisi sp a r t i c u l a r l yt r u ew h e n
patients develop chronic GvHD and rigorous therapy
becomes mandatory. The patient is responsible for his/
her health and investigation of the patient’sa t t i t u d e
toward preserving health is an important part of the
communication process. Wisdom in patients may be
particularly crucial in contemporary medicine [32].
Another important aspect concerns the availability of
competent support from significant family members or
caregivers. The patient needs to receive loving care in a
comfortable setting. Therefore, although the final deci-
sion lies with the patient, not every patient is suitable
for HSCT. In order to choose the best candidates for
HSCT, we must carefully consider all of the aforesaid
elements. Synthetically, patients should have: 1 - exten-
sive knowledge of the potential risks associated with the
procedure; 2 -strong support from caregivers; 3 - a
responsible attitude toward their health.
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attempt to precisely “calculate” each of these elements is
not the best way to decide. Rather, our opinion is that
doctors ought to strive to be wise and, in particular,
carefully assess all relevant elements in order to select
the best patients.
In contemplating the use of healthy subjects in clinical
trials, Hans Jonas, speaking about the process of
informed consent, suggests the rule of “descending
order”. He affirms that the more patients lack in knowl-
edge, motivations, freedom and responsibility, the more
we must be prudent and thrifty [33]. In unrelated
HSCT, this rule is particularly appropriate and could be
said in this way: the more patients lack the three funda-
mental characteristics mentioned above, the more the
physician needs to be careful in considering patients eli-
gible for HSCT and, alternatively, should consider the
possibility of continuing conventional therapy.
Summary
The fundamental goal of medicine is to help a sick per-
son in need and to enhance the quality of life of the
individual being treated. HSCT is a procedure consistent
with this goal and represents a valid alternative to the
conventional treatment of thalassemia. However, consid-
ering that high risk thalassemia patients have an
increased risk of treatment-related mortality, the con-
cept of conscious consent becomes particularly impor-
tant. Throughout the entire decision-making process,
every effort should be made to sustain and enhance the
autonomous choice of the patient. The physician must
use communication skills that enable the patient to fully
understand the favourable and adverse outcomes of the
procedure. Although it is his duty to illustrate the possi-
bility of completely restoring health, considerable
emphasis must be put on the adverse effects of the pro-
cedure, particularly the possibility of dying and the
development of severe acute and/or chronic GvHD.
Finally, the physician must decide whether the patient is
a suitable candidate for unrelated HSCT according to
the “rule of descending order” that accounts for the
patient’s educational, social, cultural and family back-
ground besides his/her overall ability to comprehend.
The combination of all these factors will ensure that
patients fully understand the advantages and disadvan-
tages of the procedure as well as the importance of
competent support from relatives and/or caregivers dur-
ing the pre- and post-transplantation period. The
patient must be made aware that he/she will be partly
responsible for the outcome. Full details on self-care
and fundamental lifestyle changes are mandatory. Only
if all these conditions are satisfied can it be considered
reasonable to propose unrelated HSCT as a potential
cure for high risk thalassemia patients.
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